(Q43568109)

24 November 2017

Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage (English)

1 reference

24 November 2017

1 reference

4

1 reference

24 November 2017

Fornai F

1

1 reference

24 November 2017

Battaglia G

2

1 reference

24 November 2017

Gesi M

3

1 reference

24 November 2017

Nicoletti F

5

1 reference

24 November 2017

Ruggieri S

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

24 November 2017

1 reference

24 November 2017

898

1 reference

24 November 2017

1

1 reference

24 November 2017

27-35

1 reference

Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Does levodopa aggravate Parkinson's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Effects of D1 and D2 antagonists on basal and apomorphine decreased body temperature in mice and rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

The effects of selective dopamine receptor agonists and antagonists on body temperature in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

The role of the locus coeruleus in the development of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Apomorphine protects against MPTP-induced neurotoxicity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Dopamine agonists in Parkinson's disease: a look at apomorphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Dopamine transporters and neuronal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Neurochemical and neurogenetic correlates of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Effects on body temperature in mice differentiate between dopamine D2 receptor agonists with high and low efficacies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Inhibition of monoamine oxidase by d-methamphetamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

The ontogeny of aggregation-enhanced toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

Involvement of dopamine receptor subtypes in mouse thermoregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2801%2902125-4

10.1016/S0006-8993(01)02125-4

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference